ADAR1 Capital’s Steady Buy‑In Builds 8.5% Stake in Tenax Therapeutics as Shares Rally from Year‑End Decline

Insider Buying Fuels Optimism Amid a Volatile Share Price The latest filing shows ADAR1 Capital Management, LLC purchasing 336,528 shares of Tenax Therapeutics on October 19, 2026 at an average price of $1.51 per share. Over the next two days the fund added a further 254,342 and 331,979 shares, bringing its total stake to 7,447,000 shares—roughly 8.5 % of the company’s diluted shares outstanding. The cumulative outlay of $2.3 million came at a time when Tenax’s stock has rebounded 6.2 % this week after a 13 % monthly decline and a staggering 78 % year‑to‑date drop.

What Does This Mean for Investors? ADAR1’s consistent, dollar‑cost‑averaged purchases suggest a long‑term view rather than a short‑term swing trade. The fund has been building a position since early September, buying between $1.78 and $1.63 per share, and now holds a sizable block at the current market price. For shareholders, this activity can be a bullish signal: a sophisticated institutional investor sees value in Tenax’s specialty drug platform, especially as the company advances its levosimendan‑based therapies for pulmonary hypertension. However, the stock’s negative earnings ratio (-1.03) and recent volatility warn that the upside may be tempered by continued operational risks and a crowded biopharma field.

ADAR1 Capital Management: A Pattern of Patience and Opportunism ADAR1’s historical transactions reveal a disciplined approach. Since September 2026, the fund has accumulated shares in increments of 100‑k to 900‑k, averaging purchase prices between $1.75 and $1.80. The fund’s holdings grew from 4.03 million shares in early August to 7.45 million by mid‑October. The pattern—steady buying at lower price levels followed by gradual accumulation—indicates a belief that the company’s valuation is below its intrinsic worth. ADAR1’s strategy contrasts with sporadic insider trades by executives, who have only made modest purchases (e.g., CEO Christopher Giordano’s $6,000 to $4,850 shares in September) and largely held options.

Implications for Tenax’s Future Trajectory If ADAR1’s stake continues to grow, the company could benefit from increased liquidity and a more stable share price, easing the path for future capital raises. Moreover, the fund’s involvement may encourage other institutional investors to follow suit, potentially improving market perception and reducing the cost of capital. Yet, the broader market’s negative sentiment—reflected in a 0‑point buzz and neutral sentiment score—suggests that any upside will need to be accompanied by clear clinical milestones and regulatory approvals.

Bottom Line for Investors The current insider buying spree by ADAR1 Capital Management signals confidence in Tenax Therapeutics’ therapeutic pipeline and business model. For investors, the move is worth monitoring: a growing institutional stake can help support the stock during a recovery phase, but it should be weighed against the company’s earnings volatility and the broader competitive landscape in biotech. Keeping an eye on ADAR1’s future filings will provide a barometer of institutional sentiment and help gauge whether the current price rally is sustainable or a temporary correction.